Chemokine expression in peripheral tissues from the monosodium iodoacetate model of chronic joint pain

Molecular Pain

Volumn 9, Issue 1, 2013, Pages

  Dawes, John M ^a   Kiesewetter, Hannes ^b   Perkins, James R ^c   Bennett, David L H ^a   McMahon, Stephen B ^b  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Chemokine; Macrophages; Monosodium iodoacetate; Neutrophils; Osteoarthritis; Pain

Indexed keywords

ARTEMIN; CCL9 CHEMOKINE; CHEMOKINE; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; IODOACETIC ACID; LEUKEMIA INHIBITORY FACTOR; MACROPHAGE DERIVED CHEMOKINE; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 3; MONOSODIUM IODOACETATE; STEM CELL FACTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTHRALGIA; ARTICLE; CCL2 GENE; CCL7 GENE; CCL9 GENE; CHRONIC PAIN; CONTROLLED STUDY; GENE EXPRESSION REGULATION; LYMPHOCYTIC INFILTRATION; MACROPHAGE FUNCTION; MALE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; OSTEOARTHRITIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; RAT; REAL TIME POLYMERASE CHAIN REACTION;

ANIMALS; ARTHRITIS, EXPERIMENTAL; CHEMOKINE CCL2; CHEMOKINE CCL7; CHEMOKINES; CHEMOKINES, CC; CHRONIC PAIN; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION; IODOACETATES; KNEE JOINT; MALE; RATS; RATS, WISTAR;

EID: 84887379210     PISSN: None     EISSN: 17448069     Source Type: Journal    
DOI: 10.1186/1744-8069-9-57     Document Type: Article

References (66)

1. Goldring MB. The role of the chondrocyte in osteoarthritis. Arthritis Rheum 2000, 43(9):1916-1926. 10.1002/1529-0131(200009)43:9<1916::AID-ANR2>3.0.CO;2-I, 11014341.
2. Burrage PS, Mix KS, Brinckerhoff CE. Matrix metalloproteinases: role in arthritis. Front Biosci 2006, 11:529-543. 10.2741/1817, 16146751.
3. Borzi RM, et al. Chemokines in cartilage degradation. Clin Orthop Relat Res 2004, 427(Suppl):S53-S61.
4. Kapoor M, et al. Role of proinflammatory cytokines in the pathophysiology of osteoarthritis. Nat Rev Rheumatol 2011, 7(1):33-42. 10.1038/nrrheum.2010.196, 21119608.
5. Creamer P, Hunt M, Dieppe P. Pain mechanisms in osteoarthritis of the knee: effect of intraarticular anesthetic. J Rheumatol 1996, 23(6):1031-1036.
6. Wylde V, et al. Persistent pain after joint replacement: prevalence, sensory qualities, and postoperative determinants. Pain 2011, 152(3):566-572. 10.1016/j.pain.2010.11.023, 21239114.
7. Mason L, et al. Topical NSAIDs for chronic musculoskeletal pain: systematic review and meta-analysis. BMC Musculoskelet Disord 2004, 5:28. 10.1186/1471-2474-5-28, 516039, 15317652.
8. Crichton B, Green M. GP and patient perspectives on treatment with non-steroidal anti-inflammatory drugs for the treatment of pain in osteoarthritis. Curr Med Res Opin 2002, 18(2):92-96. 10.1185/030079902125000345, 12017216.
9. Lane NE, et al. Tanezumab for the treatment of pain from osteoarthritis of the knee. N Engl J Med 2010, 363(16):1521-1531. 10.1056/NEJMoa0901510, 20942668.
10. Ng SC, Chan FK. NSAID-induced gastrointestinal and cardiovascular injury. Curr Opin Gastroenterol 2010, 26(6):611-617. 10.1097/MOG.0b013e32833e91eb, 20948372.
11. Verri WA, et al. Hypernociceptive role of cytokines and chemokines: targets for analgesic drug development?. Pharmacol Ther 2006, 112(1):116-138. 10.1016/j.pharmthera.2006.04.001, 16730375.
12. Woolf CJ, et al. Cytokines, nerve growth factor and inflammatory hyperalgesia: the contribution of tumour necrosis factor alpha. Br J Pharmacol 1997, 121(3):417-424. 10.1038/sj.bjp.0701148, 1564704, 9179382.
13. Cunha FQ, et al. The pivotal role of tumour necrosis factor alpha in the development of inflammatory hyperalgesia. Br J Pharmacol 1992, 107(3):660-664. 10.1111/j.1476-5381.1992.tb14503.x, 1907751, 1472964.
14. Qin X, Wan Y, Wang X. CCL2 and CXCL1 trigger calcitonin gene-related peptide release by exciting primary nociceptive neurons. J Neurosci Res 2005, 82(1):51-62. 10.1002/jnr.20612, 16047385.
15. Suri S, et al. Neurovascular invasion at the osteochondral junction and in osteophytes in osteoarthritis. Ann Rheum Dis 2007, 66(11):1423-1428. 2111605, 17446239.
16. Mach DB, et al. Origins of skeletal pain: sensory and sympathetic innervation of the mouse femur. Neuroscience 2002, 113(1):155-166. 10.1016/S0306-4522(02)00165-3, 12123694.
17. Pereira da Silva JA, Carmo-Fonseca M. Peptide containing nerves in human synovium: immunohistochemical evidence for decreased innervation in rheumatoid arthritis. J Rheumatol 1990, 17(12):1592-1599.
18. Bohnsack M, et al. Distribution of substance-P nerves inside the infrapatellar fat pad and the adjacent synovial tissue: a neurohistological approach to anterior knee pain syndrome. Arch Orthop Trauma Surg 2005, 125(9):592-597. 10.1007/s00402-005-0796-4, 15891922.
19. Bove SE, et al. Weight bearing as a measure of disease progression and efficacy of anti-inflammatory compounds in a model of monosodium iodoacetate-induced osteoarthritis. Osteoarthritis Cartilage 2003, 11(11):821-830. 10.1016/S1063-4584(03)00163-8, 14609535.
20. Fernihough J, et al. Pain related behaviour in two models of osteoarthritis in the rat knee. Pain 2004, 112(1-2):83-93.
21. Guzman RE, et al. Mono-iodoacetate-induced histologic changes in subchondral bone and articular cartilage of rat femorotibial joints: an animal model of osteoarthritis. Toxicol Pathol 2003, 31(6):619-624.
22. Ivanavicius SP, et al. Structural pathology in a rodent model of osteoarthritis is associated with neuropathic pain: increased expression of ATF-3 and pharmacological characterisation. Pain 2007, 128(3):272-282. 10.1016/j.pain.2006.12.022, 17276007.
23. Harvey VL, Dickenson AH. Behavioural and electrophysiological characterisation of experimentally induced osteoarthritis and neuropathy in C57Bl/6 mice. Mol Pain 2009, 5:18. 10.1186/1744-8069-5-18, 2678995, 19379487.
24. Vermeirsch H, et al. Evaluation of pain behavior and bone destruction in two arthritic models in guinea pig and rat. Pharmacol Biochem Behav 2007, 87(3):349-359. 10.1016/j.pbb.2007.05.010, 17583780.
25. Ogbonna AC, et al. Pain-like behaviour and spinal changes in the monosodium iodoacetate model of osteoarthritis in C57Bl/6 mice. Eur J Pain 2013, 17(4):514-526. 10.1002/j.1532-2149.2012.00223.x, 23169679.
26. Combe R, Bramwell S, Field MJ. The monosodium iodoacetate model of osteoarthritis: a model of chronic nociceptive pain in rats?. Neurosci Lett 2004, 370(2-3):236-240.
27. Pomonis JD, et al. Development and pharmacological characterization of a rat model of osteoarthritis pain. Pain 2005, 114(3):339-346. 10.1016/j.pain.2004.11.008, 15777859.
28. Aley KO, McCarter G, Levine JD. Nitric oxide signaling in pain and nociceptor sensitization in the rat. J Neurosci 1998, 18(17):7008-7014.
29. Hancock CM, Riegger-Krugh C. Modulation of pain in osteoarthritis: the role of nitric oxide. Clin J Pain 2008, 24(4):353-365. 10.1097/AJP.0b013e31815e5418, 18427234.
30. Dawes JM, et al. CXCL5 mediates UVB irradiation-induced pain. Sci Transl Med 2011, 3(90):90ra60. 10.1126/scitranslmed.3002193, 3232447, 21734176.
31. Haider S, Pal R. Integrated Analysis of Transcriptomic and Proteomic Data. Curr Genomics 2013, 14(2):91-110. 3637682, 24082820.
32. Thacker MA, et al. Pathophysiology of peripheral neuropathic pain: immune cells and molecules. Anesth Analg 2007, 105(3):838-847. 10.1213/01.ane.0000275190.42912.37, 17717248.
33. Clements KM, et al. Cellular and histopathological changes in the infrapatellar fat pad in the monoiodoacetate model of osteoarthritis pain. Osteoarthritis Cartilage 2009, 17(6):805-812. 10.1016/j.joca.2008.11.002, 19114312.
34. Strassle BW, et al. Inhibition of osteoclasts prevents cartilage loss and pain in a rat model of degenerative joint disease. Osteoarthritis Cartilage 2010, 18(10):1319-1328. 10.1016/j.joca.2010.06.007, 20633675.
35. Orita S, et al. Pain-related sensory innervation in monoiodoacetate-induced osteoarthritis in rat knees that gradually develops neuronal injury in addition to inflammatory pain. BMC Musculoskelet Disord 2011, 12:134. 10.1186/1471-2474-12-134, 3142251, 21679434.
36. Thakur M, et al. Characterisation of a peripheral neuropathic component of the rat monoiodoacetate model of osteoarthritis. PLoS One 2012, 7(3):e33730. 10.1371/journal.pone.0033730, 3312347, 22470467.
37. Alaaeddine N, et al. Production of the chemokine RANTES by articular chondrocytes and role in cartilage degradation. Arthritis Rheum 2001, 44(7):1633-1643. 10.1002/1529-0131(200107)44:7<1633::AID-ART286>3.0.CO;2-Z, 11465714.
38. Ushiyama T, et al. Cytokine production in the infrapatellar fat pad: another source of cytokines in knee synovial fluids. Ann Rheum Dis 2003, 62(2):108-112. 1754438, 12525378.
39. Felson DT. The sources of pain in knee osteoarthritis. Curr Opin Rheumatol 2005, 17(5):624-628. 10.1097/01.bor.0000172800.49120.97, 16093843.
40. Macule F, et al. Hoffa's fat pad resection in total knee arthroplasty. Acta Orthop Belg 2005, 71(6):714-717.
41. Cunha TM, et al. Treatment with DF 2162, a non-competitive allosteric inhibitor of CXCR1/2, diminishes neutrophil influx and inflammatory hypernociception in mice. Br J Pharmacol 2008, 154(2):460-470. 2442455, 18362895.
42. Abbadie C, et al. Impaired neuropathic pain responses in mice lacking the chemokine receptor CCR2. Proc Natl Acad Sci USA 2003, 100(13):7947-7952. 10.1073/pnas.1331358100, 164693, 12808141.
43. Bogen O, et al. Dependence of monocyte chemoattractant protein 1 induced hyperalgesia on the isolectin B4-binding protein versican. Neuroscience 2009, 159(2):780-786. 10.1016/j.neuroscience.2008.12.049, 2684808, 19167466.
44. Adams DH, Lloyd AR. Chemokines: leucocyte recruitment and activation cytokines. Lancet 1997, 349(9050):490-495. 10.1016/S0140-6736(96)07524-1, 9040590.
45. Perrin FE, et al. Involvement of monocyte chemoattractant protein-1, macrophage inflammatory protein-1alpha and interleukin-1beta in Wallerian degeneration. Brain 2005, 128(Pt 4):854-866.
46. Liu T, van Rooijen N, Tracey DJ. Depletion of macrophages reduces axonal degeneration and hyperalgesia following nerve injury. Pain 2000, 86(1-2):25-32.
47. Lean JM, et al. CCL9/MIP-1gamma and its receptor CCR1 are the major chemokine ligand/receptor species expressed by osteoclasts. J Cell Biochem 2002, 87(4):386-393. 10.1002/jcb.10319, 12397598.
48. Honore P, et al. Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord. Nat Med 2000, 6(5):521-528. 10.1038/74999, 10802707.
49. Vassiliou EK, et al. Bone marrow-derived dendritic cells generated in the presence of resolvin E1 induce apoptosis of activated CD4+ T cells. J Immunol 2008, 181(7):4534-4544.
50. Oh SB, et al. Chemokines and glycoprotein120 produce pain hypersensitivity by directly exciting primary nociceptive neurons. J Neurosci 2001, 21(14):5027-5035.
51. Miller RE, et al. CCR2 chemokine receptor signaling mediates pain in experimental osteoarthritis. Proc Natl Acad Sci USA 2012, 109(50):20602-20607. 10.1073/pnas.1209294110, 3528555, 23185004.
52. Bhangoo S, et al. Delayed functional expression of neuronal chemokine receptors following focal nerve demyelination in the rat: a mechanism for the development of chronic sensitization of peripheral nociceptors. Mol Pain 2007, 3:38. 10.1186/1744-8069-3-38, 2228278, 18076762.
53. Jung H, et al. Monocyte chemoattractant protein-1 functions as a neuromodulator in dorsal root ganglia neurons. J Neurochem 2008, 104(1):254-263. 2186066, 17944871.
54. Sun JH, et al. MCP-1 enhances excitability of nociceptive neurons in chronically compressed dorsal root ganglia. J Neurophysiol 2006, 96(5):2189-2199. 10.1152/jn.00222.2006, 16775210.
55. White FA, et al. Excitatory monocyte chemoattractant protein-1 signaling is up-regulated in sensory neurons after chronic compression of the dorsal root ganglion. Proc Natl Acad Sci USA 2005, 102(39):14092-14097. 10.1073/pnas.0503496102, 1236537, 16174730.
56. Belkouch M, et al. The chemokine CCL2 increases Nav1.8 sodium channel activity in primary sensory neurons through a Gbetagamma-dependent mechanism. J Neurosci 2011, 31(50):18381-18390. 10.1523/JNEUROSCI.3386-11.2011, 22171040.
57. Schuelert N, McDougall JJ. Involvement of Nav 1.8 sodium ion channels in the transduction of mechanical pain in a rodent model of osteoarthritis. Arthritis Res Ther 2012, 14(1):R5. 3392791, 22225591.
58. Bacon K, et al. Chemokine/chemokine receptor nomenclature. J Interferon Cytokine Res 2002, 22(10):1067-1068.
59. Zhang N, et al. A proinflammatory chemokine, CCL3, sensitizes the heat- and capsaicin-gated ion channel TRPV1. Proc Natl Acad Sci USA 2005, 102(12):4536-4541. 10.1073/pnas.0406030102, 555471, 15764707.
60. Zhang N, et al. Proinflammatory chemokines, such as C-C chemokine ligand 3, desensitize mu-opioid receptors on dorsal root ganglia neurons. J Immunol 2004, 173(1):594-599.
61. Proost P, Wuyts A, Van Damme J. Human monocyte chemotactic proteins-2 and -3: structural and functional comparison with MCP-1. J Leukoc Biol 1996, 59(1):67-74.
62. Sozzani S, et al. Receptors and transduction pathways for monocyte chemotactic protein-2 and monocyte chemotactic protein-3. Similarities and differences with MCP-1. J Immunol 1994, 152(7):3615-3622.
63. Kiefer F, Siekmann AF. The role of chemokines and their receptors in angiogenesis. Cell Mol Life Sci 2011, 68(17):2811-2830. 10.1007/s00018-011-0677-7, 21479594.
64. Mapp PI, Walsh DA. Mechanisms and targets of angiogenesis and nerve growth in osteoarthritis. Nat Rev Rheumatol 2012, 8(7):390-398. 10.1038/nrrheum.2012.80, 22641138.
65. Perkins JR, et al. ReadqPCR and NormqPCR: R packages for the reading, quality checking and normalisation of RT-qPCR quantification cycle (Cq) data. BMC Genomics 2012, 13:296. 10.1186/1471-2164-13-296, 3443438, 22748112.
66. Benjamini Y, et al. Controlling the false discovery rate in behavior genetics research. Behav Brain Res 2001, 125(1-2):279-284.